人骨髓间充质干细胞免疫原性及其相关机制的实验研究
|
摘要
研究背景及意义:严重创伤、感染、肿瘤、骨病等原因所致的骨缺损在临床治疗中非常常见,治疗方法主要有自体骨移植、异体或异种骨移植、生物材料填充等。自体骨移植是治疗骨缺损最有效的方法及金标准,但自体骨往往不能满足较大骨缺损对植骨量的要求,同时会造成供骨区新的创伤;而异体或异种骨移植以及生物材料等均难以获得满意的疗效。近年来组织工程骨的研究为骨缺损修复带来了新的希望。骨髓间充质干细胞(bone marrow derived mesenchymal stem cells,MSCs)被认为是骨组织工程最佳的种子细胞。因为这种细胞取材方便,可通过穿刺获得,创伤小,取材后并发症少,细胞培养增殖快,在体内外成骨诱导环境下可分化为骨组织,而且具有多向分化潜能。
尽管自体MSCs或成骨细胞用于动物及临床个体化治疗已经取得了良好的结果,但MSCs在骨髓中含量很少,并随着年龄的增长减少;现有方法体外迅速扩增困难;而且一些自身免疫性疾病患者,其MSCs增殖能力明显减弱;且随着培养代数增加可能出现“反分化”现象和致瘤性,从而失去了细胞应有的功能和安全性。因此,自体骨髓间充质干细胞的应用会受来源和数量限制,难以满足临床“随取随用”的要求。建立同种异体MSCs种子细胞库是解决这些问题的捷径,也是组织工程从实验室走向产业化的重要前提。近年来,国内外研究发现MSCs具有免疫调节作用,已往低等级动物模型也证明同种异体种子细胞及其构建的组织工程肌腱、软骨、骨组织植入体内免疫反应轻微,不足以影响工程化组织植入体内后的修复功能,但对经成骨诱导和经炎前因子处理后骨髓间充质干细胞的免疫原性及免疫调节机制知之甚少。
本课题主要研究经成骨诱导和炎前因子处理后骨髓间充质干细胞的免疫原性,探讨其是否具有免疫调节机制,为同种异体MSCs产业化应用及最终走向临床打下基础。
实验目的:
(1)从人骨髓中分离培养hMSCs并在体外诱导成骨细胞,对其细胞生物学特性进行观察;(2)应用流式、RT-PCR和WB研究hMSCs、DOC免疫原性及经IFN-γ处理后其免疫原性的变化;(3)应用混合淋巴细胞反应(MLR)研究hMSCs、DOC及经IFN-γ处理后在不同数量、不同刺激条件、不同天数下对外周血单个核细胞(PBMCs)增殖的影响;应用ELISA研究hMSCs、DOC及经IFN-γ处理后细胞因子分泌情况,探讨hMSCs免疫调节机制,从而了解以hMSCs为种子细胞构建的同种异体组织工程移植的可行性。
实验方法:
1.人骨髓间充质干细胞生物学特性(1)无菌条件下在志愿者髂嵴处穿刺抽取20ml骨髓,经密度梯度离心分离纯化hMSCs,培养在含15%胎牛血清的F12-DMEM培养液里。(2)比较hMSCs及DOC细胞生长曲线、细胞周期。(3)FACS检测第3代hMSCs、DOC(诱导后第6、12、18天)细胞的CD14、CD29、CD34,CD44、CD45、CD105,CD166表达。(4)用四环素法、茜素红法;Ⅰ型胶原、骨钙素免疫组化染色鉴定DOC。
2.人骨髓间充质干细胞免疫原性实验研究(1)以未分化的骨髓间充质干细胞(hMSCs)为对照,采用流式细胞技术分别检测hMSCs、hMSCs+IFN-γ和诱导后第6、12、18天的DOC、DOC+WN-γ的CD40、CD40L、CD80、CD86、HLA-Ⅰ、HLA-Ⅱ等免疫相关分子的表达;(2)采用RT-PCR技术分别检测hMSCs、hMSCs+IFN-γ和诱导后第6、12、18天的DOC、DOC+WN-γ的B7-H1、B7-H4、HLA-B、HLA-DRA、HLA-DRB等免疫相关基因表达情况;(3)采用WB技术分别检测hMSCs、hMSCs+IFN-γ和诱导后第6、12、18天的DOC、DOC+IFN-γ的B7-H1、B7-H4等免疫相关因子表达情况;
3.人骨髓间充质干细胞免疫调节机制实验研究(1)应用混合淋巴细胞反应(MLR)观察(1)不同数量级hMSCs、hMSCs+IFN-γ和诱导后第18天的DOC、DOC+WN-γ对经同种异体PBMCs刺激的PBMCs增殖的影响;(2)不同数量级hMSCs、hMSCs+IFN-γ和诱导后第18天的DOC、DOC+IFN-γ对经有丝分裂原(PHA)刺激的PBMCs增殖的影响;(3)不同天数hMSCs、hMSCs+IFN-γ和诱导后第18天的DOC、DOC+IFN-γ对经同种异体PBMCs和PHA刺激的PBMCs增殖的影响;(4)应用ELISA检测hMSCs、hMSCs+IFN-γ和诱导后第18天的DOC、DOC+WN-γ其培养上清IL-2、IL-4、IL-10、TNF-α、TGF-β1和PGE2的表达情况。
实验结果:
1.人骨髓间充质干细胞生物学特性(1)细胞呈纺锤形或三角形,类似纤维细胞,旋涡样排列;原代hMSCs接种后4d,可观察到成纤维细胞样的细胞集落,9至12d长满单层培养瓶底,传代细胞4至7d长满单层;hMSCs及DOC细胞贴壁率无明显差别,生长曲线hMSCs倍增时间为38.1h,DOC为39.7h。hMSCs和DOC细胞周期比较,hMSCs细胞周期中S+G_2比例较多,G_1比例较少。表明:hMSCs生长增殖速度较DOC快。(2)第3代细胞FACS检测结果显示:分离培养的细胞CD29、CD44、CD105、CD166表达强阳性,而CD14、CD34、CD45阴性。(3)成骨诱导16d,四环素、茜素红染色见到团块状细胞中有钙盐沉积;Ⅰ型胶原、骨钙素免疫细胞化学检测见到胞浆内有大量的棕黄色颗粒。
2.人骨髓间充质干细胞免疫原性实验研究(1)FACS检测结果显示:与hMSCs组比较,hMSCs+IFN-γ组、DOC+IFN-γ组HLA-Ⅰ表达上调(P＜0.05),HLA-Ⅱ表达明显上调(P＜0.01)。(2)RT-PCR结果显示:与hMSCs组比较,DOC组表达无统计学差异,hMSCs+IFN-γ组、DOC+WN-γ组B7-H1、B7-H4、HLA-B、HLA-DRA、HLA-DRB表达明显上调(P＜0.01)。(3)WB结果显示:与hMSCs组比较,DOC18天组、DOC+IFN-γ组B7-H1表达明显上调(P＜0.01);DOC12天组、hMSCs+WN-γ组B7-H4表达上调(P＜0.05);hMSCs+WN-γ组、DOC+IFN-γ组B7-H4表达明显上调(P＜0.01)。
3.人骨髓间充质干细胞免疫调节机制实验研究(1)应用混合淋巴细胞反应(MLR)观察①实验组数量级hMSCs、hMSCs+WN-γ和诱导后第18天的DOC、DOC+FN-γ对经同种异体PBMCs刺激的PBMCs增殖均有抑制作用,其抑制作用与细胞数量成正相关,其中10~5组与10~3组相比有统计学意义,(P＜0.01)。②不同数量级hMSCs和诱导后第18天的DOC对经有丝分裂原(PHA)刺激的PBMCs增殖均有抑制作用,其抑制作用与细胞数量成正相关。与阳性对照组相比,在10~3数量级,hMSCs+IFN-γ组、DOC+IFN-γ组对经有丝分裂原(PHA)刺激的PBMCs增殖无抑制作用;hMSCs+IFN-γ和诱导后第18天的DOC+IFN-γ对经有丝分裂原(PHA)刺激的PBMCs增殖均有抑制作用,其抑制作用与细胞数量成正相关。③与阳性对照组相比,不同天数hMSCs和诱导后第18天的DOC对经同种异体PBMCs和有丝分裂原(PHA)刺激的PBMCs增殖均有抑制作用,第6天抑制作用最强;与阳性对照组相比,在第4、6、8天,hMSCs+IFN-γ和诱导后第18天的DOC+IFN-γ对经同种异体PBMCs和有丝分裂原(PHA)刺激的PBMCs增殖均有抑制作用,第8天抑制作用最强;在第2天,hMSCs+IFN-γ和DOC+IFN-γ对经同种异体PBMCs和有丝分裂原(PHA)刺激的PBMCs增殖均无抑制作用。
(2)应用ELISA检测hMSCs、hMSCs+IFN-γ和诱导后第18天的DOC、DOC+IFN-γ培养上清,均能分泌IL-2、IL-4、IL-10、TNF-α、TGF-β1和PGE2;与未经IFN-γ刺激组相比,IFN-γ刺激组各细胞因子分泌水平均显著增高(P＜0.01)。
结论:
(1)采用密度梯度离心分离人骨髓获得的细胞在形态、表面标志、多向分化能力方面都符合hMSCs的特征,在成骨诱导条件下可向成骨细胞分化,表达Ⅰ型胶原和骨钙素,是骨组织工程较理想的种子细胞。
(2)体外实验表明MSCs、DOC保持低免疫原性,在炎前细胞因子(IFN-γ)刺激下其免疫原性增强。
(3) hMSCs、hMSCs+IFN-γ和诱导后第18天的DOC、DOC+IFN-γ均可抑制同种异体PBMSc或PHA刺激的PBMCs增殖,其抑制作用与细胞数量成正相关,其机制可能是通过调控具有免疫调节作用细胞因子的分泌水平来调控免疫反应。
总之,hMSCs经成骨诱导和炎前因子处理后其免疫原性可能增高,但仍具有免疫调节作用,从而为同种异体MSCs产业化应用及最终走向临床提供理论依据。
Background:Bone defect caused by severe trauma,infection,tumors,osteonosus and so on is very common clinically,treated mainly with autogenous bone transplantation, allogeneic or xenogenic bone grafts,biomaterial replacement and other approaches. Autogenous bone grafting is the gold standard and the most effective methods for treating osseous defects,but autologous bone grafts often don't satisfy the amount of bone tissue needed for reconstruction and would bring patients new wound,the other ways have also no satisfied effect.In recent years tissue engineering bone brings new hope for bone defect repairing.MSCs(bone marrow derived mesenchymal stem cells) are considered as the optimal seed cells for bone tissue engineering.MSCs can be derived conveniently because they can be obtained through puncture only with small wounds and fewer complications, and be culturabel with rapid proliferation.Osteogenic induction in vivo and in vitro environment not only can differentiate into bone tissue,but also has more potential to differentiate.In addition,MSCs are also easily separated and cultured.
In recent years,autologous osteoblast or MSCs for the individual animal and clinical treatment has produced good results.But MSCs content in the bone marrow is low,and decreasing with age and difficult in rapid amplification in vitro.Moreover,some autoimmune diseases significantly weaken its proliferation ability in MSCs.With increased culturing algebra "anti-differentiation" phenomenon and tumor growth may appear, accompanied with the loss of cell function and the safety.Therefore,autologous MSCs is limited owing to the use of sources and quantitative restrictions and can not meet "off the shelf" requirement.Establishing allogenic seed cell bank of MSCs is the shortcuts to solve these problems.Previous studies in lower-class animals showed that grafting in engineered tendon,cartilage and bone constructed using allogeneic seeding cells elicit no visible immunologic reaction and may influence on repairing bone defect,but people know few about the immunogenicity and immunoregulation of hMSCs after Osteogenic differentiated and treated by IFN-γ.
The aim of the study is to investigate the the immunogenicity and immunoregulation of hMSCs after Osteogenic differentiated and treated by IFN-γ,it will prepare for the further application of allogeneic hMSCs.
Objective:(1)To observed hMSCs isolated and cultured in vitro and induced osteoblast,and its characteristics in cell biology were;(2)To investigate the immunogenicity of hMSCs、Osteogenic cells differentiated from mesenchymal stem cells(DOC) and treated after IFN-γby FACS、RT-PCR and WB;(3)To explore the immunomodulatory mechanisms of hMSCs、DOC and treated after IFN-γby MLR under different conditions on peripheral blood mononuclear and cytokine secretion by ELISA.
Material and methods:1.The biological characteristics of hMSCs.(1) Under aseptic conditions,about 20ml bone marrow was aspirated from ailiac crest of volunteer. hMSCs obtained by density gradient centrifugation and purification from bone marrow, were cultured with 15%fetal bovine serum in the culture medium F12-DMEM.(2) The growth curve and the growth cycle of hMSCs and DOC cells are detected and compared.(3) (The expression of CD14,CD29,CD34,CD44,CD45,CD105,CD166 in the third generation cell are dectcted by FACS.4) hMSCs differentiated into osteoblast were identified using tetracycline,alizarin red;collagenⅠand osteocalcin immunohistochemical staining.
2.Experiment on immunogenicity of hMSCs、DOC、hMSCs+IFN-γ、DOC+IFN-γ.(1) Undifferentiated hMSCs was used as control group,investigated the expression of CD40、CD40L、CD80、CD86、HLA-Ⅰ、HLA-Ⅱof hMSCs、hMSCs+IFN-γ;DOC、DOC+IFN-γin day6、day12、day18.(2)Gene expression of B7-H1、B7-H4、HLA-B、HLA-DRA、HLA-DRB of hMSCs、hMSCs+IFN-γ;DOC、DOC+IFN-γin day6、day12、day18 were detected by RT-PCR.(3) Gene expression of B7-H1、B7-H4 of hMSCs、hMSCs+IFN-γ; DOC、DOC+IFN-γin day6、day12、day 18 were detected by WB.
3.Experiment on immunoregulation of hMSCs、DOC、hMSCs+IFN-γ、DOC+IFN-γ. (1) By mixed lymphocyte reaction(MLR)the following were observed:①Effect on PBMCs proliferation stimulated by allograft PBMCs of different magnitude of hMSCs、hMSCs+IFN-γ;DOC、DOC+IFN-γin dayl8;②Effect on PBMCs proliferation of hMSCs、 hMSCs+IFN-γ;DOC、DOC+IFN-γin day18 by mitogen-stimulated;③Effect on PBMCs proliferation stimulated by allograft PBMCs and mitogen of different days of 10~4hMSCs、hMSCs+IFN-γ;DOC、DOC+IFN-γin day18;(2) To detected the expression of IL-2、IL-4、IL-10、TNF-α、TGF-β1 and PGE2 in their culture supernatant by ELISA.
Results:1.The biological characteristics of human MSCs.(1)The characteristics of hMSCs:cells appearance presented cambiform or triangular-shaped,fibroblasts-like and vortex-like.Four days of hMSCs of original generation,the fibroblast-like cell colony was observed,and hMSCs have fulfilled the bottom of the monolayer cultural bottle in 9-12 days,while the passage cells having done in 4-7 days;There was no obvious difference in adherence of DOC and hMSCs.Doubling time in Growth curve of hMSCs was 38.1h,and DOC was 39.7h.Compared with the cell cycle of DOC,hMSCs accounted for larger proportion in S+G2 phase of cell cycle,relatively small proportion in G1 phase.These suggested that hMSCs proliferated and growed faster than DOC.(2) The third generation was showed by FACS that expression of CD29,CD44,CD105 and CD166 was strong positive in the cultured cells,and expression of CD14,CD34 and CD45 is negative.(3) On 16~(th)d after osteogenic induction,there were a lot of calcium deposition in the massive cells with Alizarin red and tetracycline staining;there were lots of brown-positive cells by osteocalcin and collagenⅠimmunocytochemical staining.
2.Experiment on immunogenicity of hMSCs、hMSCs+IFN-γ、DOC、DOC+IFN-γ. (1) Undifferentiated hMSCs was used as control group,results by FACS showed that expression of HLA-Ⅰincreased in hMSCs+IFN-γgroup and DOC+IFN-γgroup(P＜0.05); morever,expression of HLA-Ⅱincreased significantly(P＜0.01).(2) Undifferentiated hMSCs was used as control group,results by RT-PCR showed that expression of B7-H1、B7-H4、HLA-B、HLA-DRA、HLA-DRB significantly increased expression in hMSCs+ IFN-γgroup and DOC+IFN-group(P＜0.01).(3) Undifferentiated hMSCs was used as control group,results by WB showed that expression of B7-H1、B7-H4 significantly increased expression in hMSCs+ IFN-γgroup and DOC+IFN-group(P＜0.01).
3.Experiment on immunoregulation of hMSCs、hMSCs+IFN-γ、DOC、DOC+IFN-γ. (1) By mixed lymphocyte reaction(MLR)the following were founded:①Different magnitude of hMSCs、hMSCs+IFN-γ;DOC、DOC+IFN-γin day18 can inhibit the proliferation of PBMCs stimulated by allograft PBMCs.The inhibition effects correlated with cell quantity positively,there is statistics evaluation between 10~5 magnitude and 10~3 magnitude(P＜0.01).②Different magnitude of hMSCs、DOC can inhibited the proliferation of PBMCs stimulated by mitogen.Besides the 10~3 magnitude,Different magnitude of hMSCs+IFN-γ、DOC+IFN-γin day18 can inhibited the proliferation of PBMCs stimulated by mitogen,The inhibition effects correlated with cell quantity positively,PBMC proliferation.Inhibition effects correlated with cell quantity positively.③In different days,10~4 magnitude hMSCs and DOC can inhibited the proliferation of PBMCs stimulated by allograft PBMCs and mitogen.The lowest peak appear in sixth day;Besides the second day,10~4 magnitude hMSCs+IFN-γand DOC+IFN-γcan inhibited the proliferation of PBMCs.(2) hMSCs、hMSCs+IFN-γ;DOC、DOC+IFN-γin day18 could secrete IL-2、IL-4、IL-10、TNF-αin low level;TGF-β1、and PGE2 in high level; compared to the group without the stimulation of IFN-γ,all of cytokine increase of group stimulated after IFN-γand some cytokine have statistics evaluation(P＜0.01).
Conclusions:(1) The cells obtained from dissociating red marrow by density gradient centrifugation have matched the hMSCs features in aspects of appearance,cell surface marker and multi-directional differentiation ability,it can be differentiated into osteoblast, and express collagenⅠand osteocalcin under the inducible conditions.
(2) In vitro experiments show the progeny of hMSCs and DOC remains low immuogenicity,but the proinflammatory cytokine stimulation enhance the immunogenicity.
(3) Besides PHA group,Different magnitude of hMSCs,hMSCs+IFN-γ;DOC、DOC+IFN-γin day18 can inhibited the proliferation of PBMCs stimulated by allograft PBMCs.The inhibition effects correlated with cell quantity positively,which can regulate immune responses by probably secreting cytokines level for immune regulatory role.
In short,allogeneic hMSCs may be good and effective choice for tissue engineering.
尽管自体MSCs或成骨细胞用于动物及临床个体化治疗已经取得了良好的结果,但MSCs在骨髓中含量很少,并随着年龄的增长减少;现有方法体外迅速扩增困难;而且一些自身免疫性疾病患者,其MSCs增殖能力明显减弱;且随着培养代数增加可能出现“反分化”现象和致瘤性,从而失去了细胞应有的功能和安全性。因此,自体骨髓间充质干细胞的应用会受来源和数量限制,难以满足临床“随取随用”的要求。建立同种异体MSCs种子细胞库是解决这些问题的捷径,也是组织工程从实验室走向产业化的重要前提。近年来,国内外研究发现MSCs具有免疫调节作用,已往低等级动物模型也证明同种异体种子细胞及其构建的组织工程肌腱、软骨、骨组织植入体内免疫反应轻微,不足以影响工程化组织植入体内后的修复功能,但对经成骨诱导和经炎前因子处理后骨髓间充质干细胞的免疫原性及免疫调节机制知之甚少。
本课题主要研究经成骨诱导和炎前因子处理后骨髓间充质干细胞的免疫原性,探讨其是否具有免疫调节机制,为同种异体MSCs产业化应用及最终走向临床打下基础。
实验目的:
(1)从人骨髓中分离培养hMSCs并在体外诱导成骨细胞,对其细胞生物学特性进行观察;(2)应用流式、RT-PCR和WB研究hMSCs、DOC免疫原性及经IFN-γ处理后其免疫原性的变化;(3)应用混合淋巴细胞反应(MLR)研究hMSCs、DOC及经IFN-γ处理后在不同数量、不同刺激条件、不同天数下对外周血单个核细胞(PBMCs)增殖的影响;应用ELISA研究hMSCs、DOC及经IFN-γ处理后细胞因子分泌情况,探讨hMSCs免疫调节机制,从而了解以hMSCs为种子细胞构建的同种异体组织工程移植的可行性。
实验方法:
1.人骨髓间充质干细胞生物学特性(1)无菌条件下在志愿者髂嵴处穿刺抽取20ml骨髓,经密度梯度离心分离纯化hMSCs,培养在含15%胎牛血清的F12-DMEM培养液里。(2)比较hMSCs及DOC细胞生长曲线、细胞周期。(3)FACS检测第3代hMSCs、DOC(诱导后第6、12、18天)细胞的CD14、CD29、CD34,CD44、CD45、CD105,CD166表达。(4)用四环素法、茜素红法;Ⅰ型胶原、骨钙素免疫组化染色鉴定DOC。
2.人骨髓间充质干细胞免疫原性实验研究(1)以未分化的骨髓间充质干细胞(hMSCs)为对照,采用流式细胞技术分别检测hMSCs、hMSCs+IFN-γ和诱导后第6、12、18天的DOC、DOC+WN-γ的CD40、CD40L、CD80、CD86、HLA-Ⅰ、HLA-Ⅱ等免疫相关分子的表达;(2)采用RT-PCR技术分别检测hMSCs、hMSCs+IFN-γ和诱导后第6、12、18天的DOC、DOC+WN-γ的B7-H1、B7-H4、HLA-B、HLA-DRA、HLA-DRB等免疫相关基因表达情况;(3)采用WB技术分别检测hMSCs、hMSCs+IFN-γ和诱导后第6、12、18天的DOC、DOC+IFN-γ的B7-H1、B7-H4等免疫相关因子表达情况;
3.人骨髓间充质干细胞免疫调节机制实验研究(1)应用混合淋巴细胞反应(MLR)观察(1)不同数量级hMSCs、hMSCs+IFN-γ和诱导后第18天的DOC、DOC+WN-γ对经同种异体PBMCs刺激的PBMCs增殖的影响;(2)不同数量级hMSCs、hMSCs+IFN-γ和诱导后第18天的DOC、DOC+IFN-γ对经有丝分裂原(PHA)刺激的PBMCs增殖的影响;(3)不同天数hMSCs、hMSCs+IFN-γ和诱导后第18天的DOC、DOC+IFN-γ对经同种异体PBMCs和PHA刺激的PBMCs增殖的影响;(4)应用ELISA检测hMSCs、hMSCs+IFN-γ和诱导后第18天的DOC、DOC+WN-γ其培养上清IL-2、IL-4、IL-10、TNF-α、TGF-β1和PGE2的表达情况。
实验结果:
1.人骨髓间充质干细胞生物学特性(1)细胞呈纺锤形或三角形,类似纤维细胞,旋涡样排列;原代hMSCs接种后4d,可观察到成纤维细胞样的细胞集落,9至12d长满单层培养瓶底,传代细胞4至7d长满单层;hMSCs及DOC细胞贴壁率无明显差别,生长曲线hMSCs倍增时间为38.1h,DOC为39.7h。hMSCs和DOC细胞周期比较,hMSCs细胞周期中S+G_2比例较多,G_1比例较少。表明:hMSCs生长增殖速度较DOC快。(2)第3代细胞FACS检测结果显示:分离培养的细胞CD29、CD44、CD105、CD166表达强阳性,而CD14、CD34、CD45阴性。(3)成骨诱导16d,四环素、茜素红染色见到团块状细胞中有钙盐沉积;Ⅰ型胶原、骨钙素免疫细胞化学检测见到胞浆内有大量的棕黄色颗粒。
2.人骨髓间充质干细胞免疫原性实验研究(1)FACS检测结果显示:与hMSCs组比较,hMSCs+IFN-γ组、DOC+IFN-γ组HLA-Ⅰ表达上调(P＜0.05),HLA-Ⅱ表达明显上调(P＜0.01)。(2)RT-PCR结果显示:与hMSCs组比较,DOC组表达无统计学差异,hMSCs+IFN-γ组、DOC+WN-γ组B7-H1、B7-H4、HLA-B、HLA-DRA、HLA-DRB表达明显上调(P＜0.01)。(3)WB结果显示:与hMSCs组比较,DOC18天组、DOC+IFN-γ组B7-H1表达明显上调(P＜0.01);DOC12天组、hMSCs+WN-γ组B7-H4表达上调(P＜0.05);hMSCs+WN-γ组、DOC+IFN-γ组B7-H4表达明显上调(P＜0.01)。
3.人骨髓间充质干细胞免疫调节机制实验研究(1)应用混合淋巴细胞反应(MLR)观察①实验组数量级hMSCs、hMSCs+WN-γ和诱导后第18天的DOC、DOC+FN-γ对经同种异体PBMCs刺激的PBMCs增殖均有抑制作用,其抑制作用与细胞数量成正相关,其中10~5组与10~3组相比有统计学意义,(P＜0.01)。②不同数量级hMSCs和诱导后第18天的DOC对经有丝分裂原(PHA)刺激的PBMCs增殖均有抑制作用,其抑制作用与细胞数量成正相关。与阳性对照组相比,在10~3数量级,hMSCs+IFN-γ组、DOC+IFN-γ组对经有丝分裂原(PHA)刺激的PBMCs增殖无抑制作用;hMSCs+IFN-γ和诱导后第18天的DOC+IFN-γ对经有丝分裂原(PHA)刺激的PBMCs增殖均有抑制作用,其抑制作用与细胞数量成正相关。③与阳性对照组相比,不同天数hMSCs和诱导后第18天的DOC对经同种异体PBMCs和有丝分裂原(PHA)刺激的PBMCs增殖均有抑制作用,第6天抑制作用最强;与阳性对照组相比,在第4、6、8天,hMSCs+IFN-γ和诱导后第18天的DOC+IFN-γ对经同种异体PBMCs和有丝分裂原(PHA)刺激的PBMCs增殖均有抑制作用,第8天抑制作用最强;在第2天,hMSCs+IFN-γ和DOC+IFN-γ对经同种异体PBMCs和有丝分裂原(PHA)刺激的PBMCs增殖均无抑制作用。
(2)应用ELISA检测hMSCs、hMSCs+IFN-γ和诱导后第18天的DOC、DOC+IFN-γ培养上清,均能分泌IL-2、IL-4、IL-10、TNF-α、TGF-β1和PGE2;与未经IFN-γ刺激组相比,IFN-γ刺激组各细胞因子分泌水平均显著增高(P＜0.01)。
结论:
(1)采用密度梯度离心分离人骨髓获得的细胞在形态、表面标志、多向分化能力方面都符合hMSCs的特征,在成骨诱导条件下可向成骨细胞分化,表达Ⅰ型胶原和骨钙素,是骨组织工程较理想的种子细胞。
(2)体外实验表明MSCs、DOC保持低免疫原性,在炎前细胞因子(IFN-γ)刺激下其免疫原性增强。
(3) hMSCs、hMSCs+IFN-γ和诱导后第18天的DOC、DOC+IFN-γ均可抑制同种异体PBMSc或PHA刺激的PBMCs增殖,其抑制作用与细胞数量成正相关,其机制可能是通过调控具有免疫调节作用细胞因子的分泌水平来调控免疫反应。
总之,hMSCs经成骨诱导和炎前因子处理后其免疫原性可能增高,但仍具有免疫调节作用,从而为同种异体MSCs产业化应用及最终走向临床提供理论依据。
Background:Bone defect caused by severe trauma,infection,tumors,osteonosus and so on is very common clinically,treated mainly with autogenous bone transplantation, allogeneic or xenogenic bone grafts,biomaterial replacement and other approaches. Autogenous bone grafting is the gold standard and the most effective methods for treating osseous defects,but autologous bone grafts often don't satisfy the amount of bone tissue needed for reconstruction and would bring patients new wound,the other ways have also no satisfied effect.In recent years tissue engineering bone brings new hope for bone defect repairing.MSCs(bone marrow derived mesenchymal stem cells) are considered as the optimal seed cells for bone tissue engineering.MSCs can be derived conveniently because they can be obtained through puncture only with small wounds and fewer complications, and be culturabel with rapid proliferation.Osteogenic induction in vivo and in vitro environment not only can differentiate into bone tissue,but also has more potential to differentiate.In addition,MSCs are also easily separated and cultured.
In recent years,autologous osteoblast or MSCs for the individual animal and clinical treatment has produced good results.But MSCs content in the bone marrow is low,and decreasing with age and difficult in rapid amplification in vitro.Moreover,some autoimmune diseases significantly weaken its proliferation ability in MSCs.With increased culturing algebra "anti-differentiation" phenomenon and tumor growth may appear, accompanied with the loss of cell function and the safety.Therefore,autologous MSCs is limited owing to the use of sources and quantitative restrictions and can not meet "off the shelf" requirement.Establishing allogenic seed cell bank of MSCs is the shortcuts to solve these problems.Previous studies in lower-class animals showed that grafting in engineered tendon,cartilage and bone constructed using allogeneic seeding cells elicit no visible immunologic reaction and may influence on repairing bone defect,but people know few about the immunogenicity and immunoregulation of hMSCs after Osteogenic differentiated and treated by IFN-γ.
The aim of the study is to investigate the the immunogenicity and immunoregulation of hMSCs after Osteogenic differentiated and treated by IFN-γ,it will prepare for the further application of allogeneic hMSCs.
Objective:(1)To observed hMSCs isolated and cultured in vitro and induced osteoblast,and its characteristics in cell biology were;(2)To investigate the immunogenicity of hMSCs、Osteogenic cells differentiated from mesenchymal stem cells(DOC) and treated after IFN-γby FACS、RT-PCR and WB;(3)To explore the immunomodulatory mechanisms of hMSCs、DOC and treated after IFN-γby MLR under different conditions on peripheral blood mononuclear and cytokine secretion by ELISA.
Material and methods:1.The biological characteristics of hMSCs.(1) Under aseptic conditions,about 20ml bone marrow was aspirated from ailiac crest of volunteer. hMSCs obtained by density gradient centrifugation and purification from bone marrow, were cultured with 15%fetal bovine serum in the culture medium F12-DMEM.(2) The growth curve and the growth cycle of hMSCs and DOC cells are detected and compared.(3) (The expression of CD14,CD29,CD34,CD44,CD45,CD105,CD166 in the third generation cell are dectcted by FACS.4) hMSCs differentiated into osteoblast were identified using tetracycline,alizarin red;collagenⅠand osteocalcin immunohistochemical staining.
2.Experiment on immunogenicity of hMSCs、DOC、hMSCs+IFN-γ、DOC+IFN-γ.(1) Undifferentiated hMSCs was used as control group,investigated the expression of CD40、CD40L、CD80、CD86、HLA-Ⅰ、HLA-Ⅱof hMSCs、hMSCs+IFN-γ;DOC、DOC+IFN-γin day6、day12、day18.(2)Gene expression of B7-H1、B7-H4、HLA-B、HLA-DRA、HLA-DRB of hMSCs、hMSCs+IFN-γ;DOC、DOC+IFN-γin day6、day12、day18 were detected by RT-PCR.(3) Gene expression of B7-H1、B7-H4 of hMSCs、hMSCs+IFN-γ; DOC、DOC+IFN-γin day6、day12、day 18 were detected by WB.
3.Experiment on immunoregulation of hMSCs、DOC、hMSCs+IFN-γ、DOC+IFN-γ. (1) By mixed lymphocyte reaction(MLR)the following were observed:①Effect on PBMCs proliferation stimulated by allograft PBMCs of different magnitude of hMSCs、hMSCs+IFN-γ;DOC、DOC+IFN-γin dayl8;②Effect on PBMCs proliferation of hMSCs、 hMSCs+IFN-γ;DOC、DOC+IFN-γin day18 by mitogen-stimulated;③Effect on PBMCs proliferation stimulated by allograft PBMCs and mitogen of different days of 10~4hMSCs、hMSCs+IFN-γ;DOC、DOC+IFN-γin day18;(2) To detected the expression of IL-2、IL-4、IL-10、TNF-α、TGF-β1 and PGE2 in their culture supernatant by ELISA.
Results:1.The biological characteristics of human MSCs.(1)The characteristics of hMSCs:cells appearance presented cambiform or triangular-shaped,fibroblasts-like and vortex-like.Four days of hMSCs of original generation,the fibroblast-like cell colony was observed,and hMSCs have fulfilled the bottom of the monolayer cultural bottle in 9-12 days,while the passage cells having done in 4-7 days;There was no obvious difference in adherence of DOC and hMSCs.Doubling time in Growth curve of hMSCs was 38.1h,and DOC was 39.7h.Compared with the cell cycle of DOC,hMSCs accounted for larger proportion in S+G2 phase of cell cycle,relatively small proportion in G1 phase.These suggested that hMSCs proliferated and growed faster than DOC.(2) The third generation was showed by FACS that expression of CD29,CD44,CD105 and CD166 was strong positive in the cultured cells,and expression of CD14,CD34 and CD45 is negative.(3) On 16~(th)d after osteogenic induction,there were a lot of calcium deposition in the massive cells with Alizarin red and tetracycline staining;there were lots of brown-positive cells by osteocalcin and collagenⅠimmunocytochemical staining.
2.Experiment on immunogenicity of hMSCs、hMSCs+IFN-γ、DOC、DOC+IFN-γ. (1) Undifferentiated hMSCs was used as control group,results by FACS showed that expression of HLA-Ⅰincreased in hMSCs+IFN-γgroup and DOC+IFN-γgroup(P＜0.05); morever,expression of HLA-Ⅱincreased significantly(P＜0.01).(2) Undifferentiated hMSCs was used as control group,results by RT-PCR showed that expression of B7-H1、B7-H4、HLA-B、HLA-DRA、HLA-DRB significantly increased expression in hMSCs+ IFN-γgroup and DOC+IFN-group(P＜0.01).(3) Undifferentiated hMSCs was used as control group,results by WB showed that expression of B7-H1、B7-H4 significantly increased expression in hMSCs+ IFN-γgroup and DOC+IFN-group(P＜0.01).
3.Experiment on immunoregulation of hMSCs、hMSCs+IFN-γ、DOC、DOC+IFN-γ. (1) By mixed lymphocyte reaction(MLR)the following were founded:①Different magnitude of hMSCs、hMSCs+IFN-γ;DOC、DOC+IFN-γin day18 can inhibit the proliferation of PBMCs stimulated by allograft PBMCs.The inhibition effects correlated with cell quantity positively,there is statistics evaluation between 10~5 magnitude and 10~3 magnitude(P＜0.01).②Different magnitude of hMSCs、DOC can inhibited the proliferation of PBMCs stimulated by mitogen.Besides the 10~3 magnitude,Different magnitude of hMSCs+IFN-γ、DOC+IFN-γin day18 can inhibited the proliferation of PBMCs stimulated by mitogen,The inhibition effects correlated with cell quantity positively,PBMC proliferation.Inhibition effects correlated with cell quantity positively.③In different days,10~4 magnitude hMSCs and DOC can inhibited the proliferation of PBMCs stimulated by allograft PBMCs and mitogen.The lowest peak appear in sixth day;Besides the second day,10~4 magnitude hMSCs+IFN-γand DOC+IFN-γcan inhibited the proliferation of PBMCs.(2) hMSCs、hMSCs+IFN-γ;DOC、DOC+IFN-γin day18 could secrete IL-2、IL-4、IL-10、TNF-αin low level;TGF-β1、and PGE2 in high level; compared to the group without the stimulation of IFN-γ,all of cytokine increase of group stimulated after IFN-γand some cytokine have statistics evaluation(P＜0.01).
Conclusions:(1) The cells obtained from dissociating red marrow by density gradient centrifugation have matched the hMSCs features in aspects of appearance,cell surface marker and multi-directional differentiation ability,it can be differentiated into osteoblast, and express collagenⅠand osteocalcin under the inducible conditions.
(2) In vitro experiments show the progeny of hMSCs and DOC remains low immuogenicity,but the proinflammatory cytokine stimulation enhance the immunogenicity.
(3) Besides PHA group,Different magnitude of hMSCs,hMSCs+IFN-γ;DOC、DOC+IFN-γin day18 can inhibited the proliferation of PBMCs stimulated by allograft PBMCs.The inhibition effects correlated with cell quantity positively,which can regulate immune responses by probably secreting cytokines level for immune regulatory role.
In short,allogeneic hMSCs may be good and effective choice for tissue engineering.
引文
1.Yaszemski MJ,Payne RCS Hayes WC,et al.Evolution of bone transplantation molecular,cellar and tissue strategies to engineer human bone.Biomateria1,1996;17:175-85.
2.Crane GM,Ishaug SL,Mikos AG,et al.Bone tissue engineering.Nat-Med,1995,1(12):1322-1332.
3.Vacanti CA,Vacanti JP.Bone and cartilage reconstruction with tissue engineering approaches.Otolaryngol Clin North Am,1994,27(1):263-271.
4.Dominici M,Le Blanc K,Mueller I,et al.Minimal criteria for defining multipotent mesenchymal stromal cells:The International Society for Cellular Therapy position statement.Cytotherapy.2006;8:315-317.
5.杨志明等译,组织工程原理(原著第2版),北京:化学工业出版社出版.2006:1-2
6.Kneser U,Schaefer DJ,Polykandriotis E,et al.Tissue engineering of bone:the reconstructive surgeon's point of view.J Cell Mol Med,2006,10(1):7-19.
7 Conget PA,Minguell JJ.Phenotypical and Functional Properties of Human Bone Marrow Mesenchymal ProgenitorCells[J].J Cell Physiol,1999,181(1):67-73.
8.Kawamata T,Iseki H,Shibasaki T,et al.Enddoscopic Augmented Reality Navigation Sistem for Endo,nasal Transs—phenoidal Surgery to Treat Pituitary Tumors Techn-ical Note[J].Neurosurgery,2002,50(60):139321397.
9.朱灏,许建中,周强,等.不同年龄人骨髓间充质干细胞体外增殖及成骨分化的研究.中国矫形外科杂志,2004,12(10):759-761.
10.Ikehara S.Autoimmune diseases as stem cell disorders:normal stem cell transplant for their treatment.Int J Mol Med,1998,1:5-16
11.Maitra,B;Szekely E;Gjini K;et al.Human mesenchymal stem cells support unre-lated donor hematopoietic stem cells and suppress T-cell activation.Bone marrow Transplantation,Mar2004,Vol.33(6),597-604
12.Niemeyer P,Seckinger A,Simank HG,et al.Allogenic transplantation of human mesenchymal stem cells for tissue engineering purposes:an in vitro study[J].Orthopade 2004,33(12): 1346-1353
13. Sakaguchi S. Regulatory T cells: key controllers of immunologic self- tolerance.cell, 2001;101:455-458.
14. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-3843.
15. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferationby human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389-397.
16. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit all-ogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan de-gradation. Blood. 2004; 103:4619-4621.
17. Le Blanc K, Tammik L, Sundberg B, et al.. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand Immunol,2003;57:11-20.
18. Klyushnenkova E, Mosca JD, Zernetkina V T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005;12(1):47-57
19. Sudeepta, Aggarwal, Mark F. Pittenger Human mesenchymal stem cells modulate allogeneic immune cell responses blood. 2005;105:1815-1822.
20. Kadiyala S, Jaiswal N, Bruder S. Culture-expanded bone marrow-derived mesenchymal stem cells can regenerate a critical-sized segmental bone defect, Tissue Engineering, 1997,3(1): 173-185.
21. Bruder SP, Kraus KH, Goldberg VM,et al. The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects, J. Bone Joint Surg Am, 1998 80(7):985-996,
22. Kon EA, Corsi MA, Bianco P, et al. Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones, J Biomed Mater Res, 2000, 49(2): 328-337.
23.Lucarelli E,Donati D,Cenacchi A,et al.Bone reconstruction of large defects using bone marrow derived autologous stem cells.Transfus Apher Sci.2004,30(1):169-74.
24.柴岗,张艳,刘伟,等.组织工程骨在颅颌面骨缺损临床修复中的应用.中华医学杂志,2003,83(190):1676-1681.
25.沈兵,谢富林,谢清芳,等.自体髂骨与组织工程骨植骨的临床应用对比研究.中国修复重建外科杂志,2002,16(6):429-431.
26.Quarto R,Kutepv SM,Kon E,et al.Repair of large bone defects by autologous human bone marrow stromal cells[J].Tissue Eng,2000,6(6):669-679.
1.Ulrich M,Hans Peter W,Thomas M,et al.germany:Springer;1edition 2006,15-17
2.杨志明主编.组织工程.北京:化学工业出版社,2002:337-338
3.Haynesworth SE,Goshima J,Goldberg VM,et al.Characterization of cells with osteogenic potential from human marrow.Bone,1992;13:81
4.E1-Badri NS,Maheshwari A,Sanberg PR.Mesenchymal stem cells in autoimmune disease.Stem Cells Dev.2004 Oct;13(5):463-72.Review.
5.Klyushnenkova E,Mosca JD,Zernetkina V,et al.T cell responses to allogeneic human mesenchymal stem cells:Immunogenicity,tolerance,and suppression.J.Biomed.Sci.2005.12:47-57.
6.杨志明主编.组织工程基础与临床.成都:四川科学技术出版社,2000:124-130.
7.Flucker,P J.C.Induction of T cell development and establishment of T cell com-petence from embryonic stem cells differentiated in vitro.Nat Immunol 2004 5:410-417
8.Friendenstein A,Petrakova K,Kurolesova A,et al.Heterotopic transplants of bone marrow,Analysis of precursor cells,for osteogenic and hematotoxic tissues.Trans-plantation.1968,6:230-247
9.Piersma AH,Brockbank KG,Ploemacher RE,et al.Characterization of fibroblast-ic stromal cells from murine bone marrow.Exp Hematol,1985,13:237-243
10.Owen M.Marrow stromal stem cells.J Cell Sci Suppl,1988,10:63-76.
11.杨志明,余希杰,解慧琪,等.不同来源成骨细胞生物学特性的比较研究[J].中华创伤杂志,2001,17(1):10-1
12.Vlasselaer PV,Falla N,Snoeck H,et al.Characterization and purification of osteo-genic cells from murine bone marrow by two-color cell sorting using anti-Sca-1 mon-oclonal antibody and wheat germ sgglutinin[J].Blood,1994,84(3):753-763.14
13.Victor V,Elion K,Gen S,et al.Phenotypic Changes of Adult Porcine Mesenchym-al Stem Cells Induced by Prolonged Passaging in Culture Journal of cellular phys-icology 2005;205:194-201
14.Doucet C,Ernou I,Zhang Y_2 et al Platelet lysates promote mesenchymal stem cell expansion:a safety substitute for animal serum in cell-based therapy applications.J Cell Physiol.2005 Nov;205(2):228-36.
15.Don M.Ranly,Christoph H.et al Platelet-rich plasma inhibits demineralized bone Matrix-Induced Bone Formation in Nude Mice J.Bone Joint Surg.Am.,Jan 2007;89:139-147.
16.Kasten P,Vogel J,Luginbuhl R,et al.Influence of platelet-rich plasma on osteo-genic differentiation of mesenchymal stem cells and ectopic bone formation in calcium phosphate ceramics.Tissues Organs.2006;183(2):68-79.
17.Dominici M,LeBlanc K,Mueller I,et al.Minimal criteria for defining multipotent mesenchymal stromal cells:The International Society for Cellular Therapy position statement.Cytotherapy.2006;8:315-317.
18.Conget P A,Minguell J J.Phenotypical and functional properties of huamn bone marrow mesenchymal progenitor cells[J].J Cell Physiol,1999,181(1):67-73
19.Ringe J,Kaps C,Schmitt B,et al.Porcine mesenchymal stem cells.Induction of distinct mesenchymal cell lineages[J].Cell Tissue Res,2002,307(3):321-327.
20.Lodie T,Blickarz C,Devarakonda T,et al.Systematic analysis of reportedly distinct populations of multipotent bone marrow-derived stem cells reveals a lack of distinction.Tissue Engineering,2002:8:739-751.
21.Phinney D,Kopen G,Isaacson R.et al.Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice:variations in yield,growth,and differentiation.Journal of Cellular Biochemistry,1999:72:570-585.
22.Pittenger M,Mackay A,Beck S,et al.Multilineage potential of adult human mesenchymal stem cells.Science,1999:284,143-147.
23.胡静波,蒋丹丹,周燕等,影响骨髓间充质干细胞分离效率的若干因素的研究.2005,25(6):15-19
24.Stein GS,Lian JB.Molecular mechanisms mediating proliferation/diferentiation interrelationships durig progressived development of the osteblast phenotype[J].endocr Rev,1993,14:424-442
25.Hokugo A,Ozeki M,Kawakami O,et al Augmented bone regeneration activity of platelet-rich plasma by biodegradable gelatin hydrogel.Tissue Eng 2005,11:1224- 1233
26.Meisel R,Zibert A,Laryea M,et al.Human bone marrow stromal cells inhibit all-ogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan de-gradation.Blood.2004;103:4619-4621.
1. Sullivan JA ,Oettinger HF,Sachs DH ,et all Analysis of polymorphismin porcine MHC class I genes,alteration in signal's recognized by human cytotoxic lymphocytes[J ].J Immunol, 1997 ,159 ;2318-2325
2. Silva WAJ, Covas DT, Panepucci RA, et al. The profile of gene expression of human marrow mesenchymal stein Cells[J]. Stein Cells, 2003, 21(6): 661-669.
3. Lazarus HM, Haynesworth ES, Gerson SL, et all Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal rogenitor cells); implication for therapeutic use. Bone Marrow Transplant, 1995,16 ( 4) : 557-564.
4. Maitra, B; Szekely E; Gjini K; et al. Human mesenchymal stem cells support unre-lated donor hematopoietic stem cells and suppress T-cell activation. Bone marrow Transplantation, Mar2004, Vol. 33 (6), 597-604
5. Niemeyer P, Seckinger A, Simank HG, et al. Allogenic transplantation of human mesenchymal stem cells for tissue engineering purposes: an in vitro study [J].Orthopade 2004,33(12): 1346-1353
6. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance.cell,2001; 101:455-458.
7. Plumas, J Chaperot, L Richard, MJ, et al. Mesenchymal stem cells induce apoptosis of activated T cells.Leukemia,2005,19(9): 1597-1604
8. Pascher A , Poehlein C ,Stangl M,et all Application of immunoapheresis for delayi-ng hyperacute rejection during isolated xenogeneic pig liver perfusion[J ].transpla-ntation , 1997,63 :86-71
9. Candinas D ,Bach FH , Hancok WW1 Delayed xenograft rejection in complement-depleted T-cell-deficient rat recipients of guinea pig cardiac grafts[J ].Transplant Proc , 1996 ,28 :67-81
10. Ruggeri L,Capanni M,Martelli MF,et al.Cellular therapy:exploting NK cell allureactivity in transplantation[J].Curr Opin Hematol 2001,8(6):355-359.
11.Ristich V,Liang S,Zhang W,et al.Tolerization of dendritic cells by HLA -G[J].EurJ Immunol,2005,35(4): 1133-1142.
12. Gotherstrom C,Ringden O,Tammik C,et al.Immunologic propertie of human fetal mesenchymal stem cells[J].Am J Obstet Gynecol 2004,190(1):239-245.
13.X u XL, Tang T, Dai, et al. K Immune response and effect of adenovirus mediated human BMP-2 gene transfer on the repair of segmental tibial bone defects in goats. Acta Orthop 2005; 76(5):637-646.
14. ZhangW, GeW, Li C, et al. Effects ofmesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem CellsDev, 2004; 13:263-271.
15. Sun S, Guo Z, Xiao X. Isolation ofmouse marrow mesenchymal p rogenitors by a novel and reliable method [ J ]. Stem Cells, 2003, 21 (5) : 527 - 535.
16. Dong H,Zhu G,Tamada K,et al.B7-H1,a third member of the B7 family,costimulates T-cell proliferation and secretion of interleukin 10 [J].Nat Med,1999,5:1365-1369.
17. Dong H,Strome SE,Matteson EL,et al.costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis [J]. J Clin Invest, 2003,111:363-370.
18. Dong H,Strome SE,Salomao DR,et al.Tumor associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion [J]. Nat Med, 2002,8:793-800.
19. Mazanet MM,Hughes CC. B7-H1 is expressed by human endothelial cell and suppresses T cell cytokine synthesis [J]. J Immunol,2002,169:3581-3588.
20. Schreiner B,Mitsdoerffer M,Kieseier BC,et al. Interferon beta enhances monocyte and dendritic cell expression of B7-H1(PD-L1), a strong inhibitor of autologous T-cell activation:relevance for the immunemodulatory effect in multiple sclerosis [J]. J Neuroimmunol,2004,155(122): 172-182.
21.Tamura H,Dong H,Zhu G,et al.B7-Hl costimulation preferentially enhances CD28" independent T-helper cell function [J]. Blood, 2001,97:1809-1816.
22. Gray CP,Arosio P,Hersey P. Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells [J]. Blood,2002,99:33263-3334.
23. Blank C, Brown I, Peterson AC,et al. PD-LI/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8~+ T cells. Cancer Res, 2004, 64: 1140-1145.
24. SICA GL, CHOI IH, ZHU G, et al. B7-H4 , a molecule of the B7 family, negatively regulates T cell immunity [ J] . Immunity, 2003, 18( 6) : 849- 861.
25. SEDY JR, GAVRIELI M, POTTER KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator [ J] . Nat Immunol, 2005, 6(1): 90- 98.
26. GONZALEZ LC, LOYET KM, CALEMINE-FENAUX J, et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator [ J] . Proc Natl Acad Sci USA, 2005, 102 ( 4): 1116-1121.
27. CHEN L. Co-inhibitory molecules of the B7-CD28 family in the control of T cell immunity[ J] . Nature Rev Immunol, 2004, 4: 336- 347.
1.Bartholomew A,Sturgeon C,Siatskas Metal.Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo[J].Exp Hematol 2002;30(1):42-48.
2.Sudeepta Aggarwal and Mark E Pittenger Human mesenchymal stem cells modulate allogeneic immune cell responses blood.2005;105(4):1815-1822.
3.LeBlanc K,Rasmusson I,Gotherstrom C,et al.Mesenchymal stem cells inhibit the expression of CD25(interleukin-2 receptor) and CD38 on phytohaemag glutinin activeated lymphocytes.Scand J Im munol.2004;60(3):307-15
4.Plumas,J Chaperot,L Richard,MJ,et al.Mesenchymal stem cells induce apoptosis of activated T cells.Leukemia,2005,19(9): 1597-1604
5. Butler PE; Lee WP; Sims M et al. Cell transplantation from limb allografts. Plast Reconstr Surg, 1998; 102(1): 161-8.
6. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-3843.
7. Bartholomew A, Sturgeon C, Siatskas M,et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental Hematology 30 (2002) 42-48.
8. Plumas J, Chaperot L, Richard MJ, et al. Mesenchymal stem cells induce apoptosis of activated T cells.Leukemia,2005,19(9): 1597-1604
9. Maitra B, Szekely E, Gjini K,et al.Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 2004 Jan 12.
10. Djouad F, Plence P, Bony C,et al.Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003 Nov 15; 102(10): 3837-3844.
11. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31:890-896
12. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol.2003; 57:11-20.
13. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-3843.
14. Krampera M,Glennie S,Dyson J,et al.Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen specific T cell to their cognate peptide[J].Blood,2003,101(9):3722-3729.
15.Tse WT, Pendleton JD, Beyer WM,et al.Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003 Feb 15; 75(3): 389-397.
16. Zhang Y,Li CD,Jiang XX,et al.Comparison of mesenchymal stem cells from human placenta and bone marrow [J].Chin MedJ(Eng),2004,117(6):882-887.
17. Silva WAJ,Covas DT,Panepucci RA,et al.The profile of gene expression of human marrow mesenchymal stem cells[J].Stem Cells,2003,21(6):661-669
18. Taniguchi F,Harada T,Deura I,et al.Hepatocyte growth factor promotes cell proliferation and inhibits progesterone secretion via PKA and MAPK pathways in a human granulosaxell line[J].Mol reprod dev,2004,68(3):335-344.
19. Arikawa T,Omura K,Morita I. Regulation of bone morphogenetic protein expression byendo genous prosta glandinE2 in human mesenchymal stem cells[J].JCellPhysiol, 2004,200(3):400-406.
20. Roper RL,Ludlow JW,Phipps RP.Prosta glandinE2 inhibits Blym phocyte activati-on by a cAMP dependent mechanism:PGE induc iblere gulatory proteins[J]. Cell immunol, 1994,154(1):296-308
21.Akasaki Y,Liu G,Chung NH,etal.Induction of a CD4+Tregutory typel response by cyclooxygenase 2 overexpressingglioma[J]JImmunol,2004,173(7):4352-4359.
22. Colgan SP.Lipid media torsin epithelial cell cell interactions[J]. Cell Mol Life Sci,2002,59(5):754-760.
23. Meisel R,Zibert A,Laryea M,etal.Human bone marrow stromal cells inhibit allogeneic T cell responses by in doleamine2,3dioxygenase mediated tryptophan degradation[J]. Blood,2004,103(12):4619-4621.
24. Frumento G,Rotondo R,Tonetti M, etal.Tryptophan derived catabolite sare responsible for inhibition of Tand natural killer cell proliferation induced by indoleamine2,3 dioxygenase[J].JExpMed,2002,196(4):459-468.
25. Yard BA, Kooymans Couthino M, Pape M E. Analysis of cytokine production by graft-infiltrating cells isolated from rejecting renal allografts. Transplantation, 1994, 57(1):153
26. Salom RN, Maguire JA, Hancock WW Mechanism of a clinicallyrelevant protocol to induce tolerance of cardiac allografts.Transplantation, 1993; 56:1309-14.
27. Ditmer R, Harfmann P, Tenschert Wet al. Monitoring of renal transplant patients with interleukin-2 and interleukin-2 receptor enzyme immunoassay and interleukin-2 receptor immunocytology.TransplantProc,1990;22:2284-5.
28.Docke WD,Randow F,Syrbe U.Monocyte deactivation in septic patients:Restoration by IFN-γ treatment.Nature Med 1997,3(6):678.
29.Sherman LA,Chatopadhyay S.The molecular basis of alloreconition Ann Rev Immunol,1993;11:385-402.
30.Devine SM,Peter S,Martin B J,et al.Mesenchymal stem cells:stealth and suppression.Cancer J,2001;7(SuppI 2):S76-82.
31.Mclntosh K,Bartholomew A.Stromal cell modulation of the immune system.A potential role for mesenchymal stem cells.Graft,2000;3:324-8
32.Maitra B,Szekely E,Gjini K,et al.Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation.Bone Marrow Transplantation,Mar2004,Vol.33(6):597
33.阳富春,杨志明,李秀群,等.组织工程化骨修复称猴长段骨缺损的实验 中国修复重建外科杂志,2003:17:406-10
34.Aggarwal S,Pittenger MF.Human mesenchymal stem cells modulate allogeneic immune cell responses.Blood.2005 Feb 15;105(4):1815-22.Epub 2004 Oct 19.
35.Eiselt P,Kim BS,Chacke B.Development of technologies aiding large-tissue engineering.Biotechnol Prog,1998;14:134-40
36.Le Blanc K,Tammik L,Sundberg B,et al:Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.Scand J Immunol.2003;57:11-20
37.Fibbe WE.Modulation of Immune responses by Mesenchymal Stem Cells.Ann N Y Acad Sci.2007 Apr 18
38.Poncelet AJ,Vercruysse J,Saliez A,et al Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro,intracardiac injection elicits an immune response in vivo.Transplantation.2007 Mar27;83(6):783-90
1. Vacanti CA,Vacanti JP.Bone and cartilage reconstruction with tissue engineering approaches.Otolaryngol Clin North Am,1994,27(1):263.
2. Crane GM,Ishaug SL,Mikos AG,et al.Bone tissue engineering.Nat-Med, 1995, 1(12): 1322.
3. Wakitani S, Saito T, Caplan A. Myogenic cells derived fromrat bone marrow mesenchymal stem cells expoed to 5-azacytidine.MuscleNerve,1995,18(12): 1417-1426.
4. Phinney DG, Kopen G, Isaacson RL, et al. Plastic adherent stromal cells from the bone marrow of commonly used strain so inbredmice: variationin yield, growth, and differentiation. J Cel Biochem,1999,72(4):570-585.
5. Hua L, David M K, Boon CH1, et al. The Immunogenicity and Immunomodulatory Function of Osteogenic Cells Differentiated from Mesenchymal Stem Cells. The Journal of Immunology, 2006, 176: 2864-2871.
6. Friedenstein, A. Stromal monocytes of bone marrow: cloning in vitro and retransplantation in vivo. In: S. Thiernfelder, Editor, Immunology of Bone Marrow Transplantation, 1980, 19.
7. Friedenstein A J,Gorskaja U, Kalugina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs.Exp Hemato,1976,1(4):267-302
8. Guo ZK, Yang JQ, Liu XD, et al. Biological features of mesenchymal stem cells from human bone marrow. Chinese Medical Journal, 2001, 114(9): 950-95.
9. Lagar'kova MA, Lyakisheva AV,Filonenko ES,et al. Characteristics of human bone marrow mesenchymal stem cells isolated by immunomagnetic selection. Bull Exp Biol Med. 2006;141(1):112-6.
10. Simmons PJ, Torok-Storb B (1991) Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 78(1):55-62 .
11. Deschaseaux F, Gindraux F, Saadi R, et al. (Direct selection of human bone marrow mesenchymal stem cells using an anti-CD49a antibody reveals their CD45~(med.low) phenotype. Br J Haematol. 2003, 122(1-2):506-517.
12. Reyes M.,. Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone marrow, J. Clin. Invest, 2002, 109 (2), 337-346.
13. Gindraux F, Selmani Z, Obert L, et al.Human and rodent bone marrow mesenchymal stem cells that express primitive stem cell markers can be directly enriched by using the CD49a molecule. Cell and Tissue Research, 2007, 327(3): 471-483.
14. Letchford J, Angharad MC, Karina S, et al. Isolation of C15: A novel antibody generated by phage display against mesenchymal stem cell-enriched fractions of adult human marrow. Journal of Immunological Methods, 2006, 308( 1-2): 124-137.
15. Stewart K, Monk P, Walsh S, et al. STRO-1, HOP-26 (CD63), CD49a and SB-10 (CD166) as markers of primitive human marrow stromal cells and their more differentiated progeny: a comparative investigation in vitro. Cell Tissue Res, 2003, 313(2):281-290
16. Guo KT, SchAfer R, Angela P, et al. A New Technique for the Isolation and Surface Immobilization of Mesenchymal Stem Cells from Whole Bone Marrow Using High-Specific DNAAptamers. Stem Cells Vol. 2006, 24(10 ): 2220-2231.
17. Tondreau T, Lagneaux L, Dejeneffe M, et al. Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential. Cytotherapy. 2004;6(4):372-379.
18. Le Blanc K, Tammik C, Zetterberg E, et al. HLA-expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol, 2003,31(10): 890-896.
19. Niemeyer P, Krause U, Punzel M, et al. Mesenchymale Stammzellen zum Tissue zngineering von Knochen: 3-D-Kultivierung und Osteogene Differenzierung auf mineralisier-tem Kollagen. Z Orthop, 2003,141 (3): 712-717.
20. Maitra B, Szekely E, Gjini K, et al. Human mesenchymal stem ceils support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant, 2004, 33(6): 597-604.
21. Rasmusson I, Ringden O, Sundberg B, et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but notactivated cytotoxic T lymphocytes or natural killer cells. Transplantation, 2003, 76(8): 1208 1213
22. Klyushnenkova E ,Mosca J ,Mclntosh K. Human mesenchymal stem cells suppress allergenic t ransplantation. Blood , 1998 ,92 :642-651.
23. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stein cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide[J]. Blod, 2003, 101(9):3722-3729.
24. Tse WT, Pendleton JD, Beyer WM. et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation[J]. Transplantation, 2003, 75(3): 389-397.
25. Le Blanc K, Rasmusson I, Gotherstrom C, et al. Mesenchymal stein cells inhibit the expression of CD25(interleukin-2 receptor)and CD38 on phytohaemagglutinin-activated lymphocytes [J]. Scand J Immunol, 2004, 60(3): 307-315.
26. Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stein cells induce division arest anergy of activated T cells[J]. Blod, 2005, 105(7): 2821-2827.
27. Wei Zhang, Wei Ge, Changhong Li, et al. Efects of mesenchymal stem cells Oil difierentiation. Maturation and funotion of human monocyte-derived dendritic Cells[J]. Stem Cells and Development, 2004, 13: 263 -271.
28. Silva WAJ, Covas DT, Panepucci RA, et al. The profile of gene expression of human marrow mesenehymal stein Cells[J]. Stein Cells, 2003, 21(6): 661-669.
29. Taniguchi F, Harada T, Deura I, et al. Hepatocyte growth factor promotes cell proliferation and inhibits progesterone secretion via PKAand MAPK pathways in a human granulosa cell line. Mol Reprod Dev, 2004, 68(3): 335-342.
30. Arikawa T, Olnura K, Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stein ceils[J]. J Cell Physiol, 2004, 200(3): 400-406.
31.Meisel R, Zibert A, Laryea M, et al. Human bone marrow strolnal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation[J]. Blod, 2004, 103(12): 4619-4621.
32. Le Blanc K, Tammik 1 , Sundberg B, el al. Mesenchymal stem cellsinhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompalm y complex[J]. Scand J Immunol, 2003, 57: 11-20.
33. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growt h in allogeneic animals. Blood ,2003 ,102(38):372-384.
34. De Kok IJ, Peter SJ, Arehambauh M, et al. Investigation of allogeneic mesenc·hyrnal stem cell—based alveolar Irene formation: preliminary findings[J]. Clin Oral Implants Res. 2003, 14: 481-489.
35. Arinzeh I'L, Peler SJ, Archambauh MP, et al. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect[J]. J Bone Joint Surg Am, 2003, 85-A: 1927-1935.
36. Hiroyuki T,Junichi H, Eric C, Engineered allogeneic mesenchymal stem cells repair femoral segmental defect in rats. Journal of Orthopaedic Research 21 (2003) 44-53
1. Kosmaczewska A, Magott-Procelewska M, Frydecka J, et al CD40L, CD28, and CTLA-4 expression on CD4~+ T cells in kidney graft Recipients a relationship with post-transplantation clinical course [J]. Transpl Immunol, 2006,16(1):32- 40.
2. Van-Berkel M E, Oostenvegel M A. CD28 and ICOS similar or separate costimulators of T cells [J]. Immunol Lett, 2006, 105(2): 115-122.
3. Borst J, Hendriks J, Xiao Y, CD27 and CD70 in T cell and B cell activation [J].Curr Opin Immunol, 2005,17( 3): 275-281.
4. Dong H,Zhu G,Tamada K,et al.B7-Hl,a third member of the B7 family,costimulates T-cell proliferation and secretion of interleukin 10 [J].Nat Med, 1999,5:1365-1369.
5. Dong H,Strome SE,Matteson EL,et al.costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis [J]. J Clin Invest, 2003,111:363-370.
6. Dong H,Strome SE,Salomao DR,et al.Tumor associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion [J]. Nat Med, 2002,8:793-800.
7. Mazanet MM,Hughes CC. B7-H1 is expressed by human endothelial cell and suppresses T cell cytokine synthesis [J]. J Immunol,2002,169:3581-3588.
8. Schreiner B,Mitsdoerffer M,Kieseier BC,et al. Interferon beta enhances monocyte and dendritic cell expression of B7-H1(PD-L1), a strong inhibitor of autologous T-cell activation:relevance for the immunemodulatory effect in multiple sclerosis [J]. J Neuroimmunol,2004,155(122):l72-182.
9. Tamura H,Dong H,Zhu G,et al.B7-Hl costimulation preferentially enhances CD28~-independent T-helper cell function [J]. Blood, 2001,97:1809-1816.
10. Gray CP,Arosio P,Hersey P. Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells [J]. Blood,2002,99:33263-3334.
11. Freeman GJ,Long AJ,Malenkovich N,et al.Enganement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J]. J Exp Med,2000,192:1027-1034.
12. Ishida Y,Agata Y,Shibahara K,et al. Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily ,upon programmed cell death [J]. EMBO J, 1992,11:3887-3895.
13. Finger LR,Pu J,Wasserman R,et al. The human PD-1 gene:complete cDNA , genomic organization , and developmentally regulated expression in B cell progenitors [J]. Gene, 1997,197:177-187.
14. Prokunina L,Castilejor opez ,Oberg ,et 1.A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans [J] .Nat Genet ,2002,32:666-669.
15. Strome SE,Dong H,Tamura H,et al.B7-Hl blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma[J]. Cancer Res, 2003,63(19):6501-6505.
16. Tyler J.Curiel,Shuang Wei,Haidong Dong,et al.Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity[J]. Nat Med, 2003,9(5):562-567.
17. Sica GL , Choi IH , Zhu G, et al . B72H4 , a molecule of the B7 family, negatively regulates T cell immunity [J] . Immunity , 2003 ,18(6): 849 - 861.
18. Zang X, Loke P , KimJ , et al. B7x : a widely expressed B7 family member that inhibits T cell activation [J ] . Proc Natl Acad Sci ,2003 ,100(18) :10 388 - 10 392.
19. Prasad DV , Richards S , Mai XM, et al . B7S1 , a novel B7 family member that negatively regulates T cell activation[J] .Immunity ,2003 ,18(6) :863 - 873.
20. Choi IH , Zhu G, Sica GL , et al . Genomic organization and expression analysis of B72H4 , an immune inhibitory molecule of the B7 family [J ] . J Immunol ,2003 ,171 (9): 4 650 -4 654.
21. Hirotsune S , Yoshida N , Chen A , et al . An expressed pseudogene regulates the messenger-RNA stability of its homologous coding gene [J] . Nature , 2003 ,423(6 935) :91 -96.
22. Anderson HA , Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation [J ] . Nat Immunol, 2000 ,1(2) : 156 - 162.
23. Tringler B , Liu W, Corral L , et al . B72H4 overexpression in ovarian tumors[J ] . Gynecol Oncol, 2006 ,100(1) :44 - 52.
24. Tringler B , Zhuo S , Pilkington G, et al . B72h4 is highly expressed in ductal and lobular breast cancer [J ] . Clin Cancer Res ,2005 ,11(5) :1 842 - 1 848.
25．李文桦,刘瑞梓,杨秀利,等．肿瘤模型中B7-H4和BTLA的异常表达[J]．中国癌症杂志,2005,15(04)：313—316．
26. Simon I, Zhuo S , Corral L , et al . B72h4 is a novel membrane2bound protein and a candidate serum and tissue biomarker for ovarian cancer [ J ] . Cancer Res , 2006 , 66 (3):1 570- 1 575.
27. Kryczek I, Zou L , Rodriguez P , et al. B72H4 expression identifies a novel supper-ssive macrophage population in human ovarian carcinoma [ J ] . J Exp Med , 2006 , 203 (4) :871 -881.
28. Salceda S , Tang T, Kmet M, et al . The immunomodulatory protein B72H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation [J ] . Exp Cell Res , 2005 ,306(1) : 128 - 141.
29. Tamada K, Shimozaki K, Chapoval AI, et al . Modulation of T-cell2mediated immunity in tumor and graft-versus2host disease models through the LIGHT co2stimulatory pathway[J] . Nat Med , 2000 ,6(3) :283 - 289.
30. Tamada K, Tamura H , Flies D , et al . Blockade of LIGHT/LT beta and CD40 signaling induces allospecific T cell anergy , preventing graft2versus2host disease [J ] . J Clin Invest, 2002 ,109(4) :549 - 557.
2.Crane GM,Ishaug SL,Mikos AG,et al.Bone tissue engineering.Nat-Med,1995,1(12):1322-1332.
3.Vacanti CA,Vacanti JP.Bone and cartilage reconstruction with tissue engineering approaches.Otolaryngol Clin North Am,1994,27(1):263-271.
4.Dominici M,Le Blanc K,Mueller I,et al.Minimal criteria for defining multipotent mesenchymal stromal cells:The International Society for Cellular Therapy position statement.Cytotherapy.2006;8:315-317.
5.杨志明等译,组织工程原理(原著第2版),北京:化学工业出版社出版.2006:1-2
6.Kneser U,Schaefer DJ,Polykandriotis E,et al.Tissue engineering of bone:the reconstructive surgeon's point of view.J Cell Mol Med,2006,10(1):7-19.
7 Conget PA,Minguell JJ.Phenotypical and Functional Properties of Human Bone Marrow Mesenchymal ProgenitorCells[J].J Cell Physiol,1999,181(1):67-73.
8.Kawamata T,Iseki H,Shibasaki T,et al.Enddoscopic Augmented Reality Navigation Sistem for Endo,nasal Transs—phenoidal Surgery to Treat Pituitary Tumors Techn-ical Note[J].Neurosurgery,2002,50(60):139321397.
9.朱灏,许建中,周强,等.不同年龄人骨髓间充质干细胞体外增殖及成骨分化的研究.中国矫形外科杂志,2004,12(10):759-761.
10.Ikehara S.Autoimmune diseases as stem cell disorders:normal stem cell transplant for their treatment.Int J Mol Med,1998,1:5-16
11.Maitra,B;Szekely E;Gjini K;et al.Human mesenchymal stem cells support unre-lated donor hematopoietic stem cells and suppress T-cell activation.Bone marrow Transplantation,Mar2004,Vol.33(6),597-604
12.Niemeyer P,Seckinger A,Simank HG,et al.Allogenic transplantation of human mesenchymal stem cells for tissue engineering purposes:an in vitro study[J].Orthopade 2004,33(12): 1346-1353
13. Sakaguchi S. Regulatory T cells: key controllers of immunologic self- tolerance.cell, 2001;101:455-458.
14. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-3843.
15. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferationby human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389-397.
16. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit all-ogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan de-gradation. Blood. 2004; 103:4619-4621.
17. Le Blanc K, Tammik L, Sundberg B, et al.. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand Immunol,2003;57:11-20.
18. Klyushnenkova E, Mosca JD, Zernetkina V T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005;12(1):47-57
19. Sudeepta, Aggarwal, Mark F. Pittenger Human mesenchymal stem cells modulate allogeneic immune cell responses blood. 2005;105:1815-1822.
20. Kadiyala S, Jaiswal N, Bruder S. Culture-expanded bone marrow-derived mesenchymal stem cells can regenerate a critical-sized segmental bone defect, Tissue Engineering, 1997,3(1): 173-185.
21. Bruder SP, Kraus KH, Goldberg VM,et al. The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects, J. Bone Joint Surg Am, 1998 80(7):985-996,
22. Kon EA, Corsi MA, Bianco P, et al. Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones, J Biomed Mater Res, 2000, 49(2): 328-337.
23.Lucarelli E,Donati D,Cenacchi A,et al.Bone reconstruction of large defects using bone marrow derived autologous stem cells.Transfus Apher Sci.2004,30(1):169-74.
24.柴岗,张艳,刘伟,等.组织工程骨在颅颌面骨缺损临床修复中的应用.中华医学杂志,2003,83(190):1676-1681.
25.沈兵,谢富林,谢清芳,等.自体髂骨与组织工程骨植骨的临床应用对比研究.中国修复重建外科杂志,2002,16(6):429-431.
26.Quarto R,Kutepv SM,Kon E,et al.Repair of large bone defects by autologous human bone marrow stromal cells[J].Tissue Eng,2000,6(6):669-679.
1.Ulrich M,Hans Peter W,Thomas M,et al.germany:Springer;1edition 2006,15-17
2.杨志明主编.组织工程.北京:化学工业出版社,2002:337-338
3.Haynesworth SE,Goshima J,Goldberg VM,et al.Characterization of cells with osteogenic potential from human marrow.Bone,1992;13:81
4.E1-Badri NS,Maheshwari A,Sanberg PR.Mesenchymal stem cells in autoimmune disease.Stem Cells Dev.2004 Oct;13(5):463-72.Review.
5.Klyushnenkova E,Mosca JD,Zernetkina V,et al.T cell responses to allogeneic human mesenchymal stem cells:Immunogenicity,tolerance,and suppression.J.Biomed.Sci.2005.12:47-57.
6.杨志明主编.组织工程基础与临床.成都:四川科学技术出版社,2000:124-130.
7.Flucker,P J.C.Induction of T cell development and establishment of T cell com-petence from embryonic stem cells differentiated in vitro.Nat Immunol 2004 5:410-417
8.Friendenstein A,Petrakova K,Kurolesova A,et al.Heterotopic transplants of bone marrow,Analysis of precursor cells,for osteogenic and hematotoxic tissues.Trans-plantation.1968,6:230-247
9.Piersma AH,Brockbank KG,Ploemacher RE,et al.Characterization of fibroblast-ic stromal cells from murine bone marrow.Exp Hematol,1985,13:237-243
10.Owen M.Marrow stromal stem cells.J Cell Sci Suppl,1988,10:63-76.
11.杨志明,余希杰,解慧琪,等.不同来源成骨细胞生物学特性的比较研究[J].中华创伤杂志,2001,17(1):10-1
12.Vlasselaer PV,Falla N,Snoeck H,et al.Characterization and purification of osteo-genic cells from murine bone marrow by two-color cell sorting using anti-Sca-1 mon-oclonal antibody and wheat germ sgglutinin[J].Blood,1994,84(3):753-763.14
13.Victor V,Elion K,Gen S,et al.Phenotypic Changes of Adult Porcine Mesenchym-al Stem Cells Induced by Prolonged Passaging in Culture Journal of cellular phys-icology 2005;205:194-201
14.Doucet C,Ernou I,Zhang Y_2 et al Platelet lysates promote mesenchymal stem cell expansion:a safety substitute for animal serum in cell-based therapy applications.J Cell Physiol.2005 Nov;205(2):228-36.
15.Don M.Ranly,Christoph H.et al Platelet-rich plasma inhibits demineralized bone Matrix-Induced Bone Formation in Nude Mice J.Bone Joint Surg.Am.,Jan 2007;89:139-147.
16.Kasten P,Vogel J,Luginbuhl R,et al.Influence of platelet-rich plasma on osteo-genic differentiation of mesenchymal stem cells and ectopic bone formation in calcium phosphate ceramics.Tissues Organs.2006;183(2):68-79.
17.Dominici M,LeBlanc K,Mueller I,et al.Minimal criteria for defining multipotent mesenchymal stromal cells:The International Society for Cellular Therapy position statement.Cytotherapy.2006;8:315-317.
18.Conget P A,Minguell J J.Phenotypical and functional properties of huamn bone marrow mesenchymal progenitor cells[J].J Cell Physiol,1999,181(1):67-73
19.Ringe J,Kaps C,Schmitt B,et al.Porcine mesenchymal stem cells.Induction of distinct mesenchymal cell lineages[J].Cell Tissue Res,2002,307(3):321-327.
20.Lodie T,Blickarz C,Devarakonda T,et al.Systematic analysis of reportedly distinct populations of multipotent bone marrow-derived stem cells reveals a lack of distinction.Tissue Engineering,2002:8:739-751.
21.Phinney D,Kopen G,Isaacson R.et al.Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice:variations in yield,growth,and differentiation.Journal of Cellular Biochemistry,1999:72:570-585.
22.Pittenger M,Mackay A,Beck S,et al.Multilineage potential of adult human mesenchymal stem cells.Science,1999:284,143-147.
23.胡静波,蒋丹丹,周燕等,影响骨髓间充质干细胞分离效率的若干因素的研究.2005,25(6):15-19
24.Stein GS,Lian JB.Molecular mechanisms mediating proliferation/diferentiation interrelationships durig progressived development of the osteblast phenotype[J].endocr Rev,1993,14:424-442
25.Hokugo A,Ozeki M,Kawakami O,et al Augmented bone regeneration activity of platelet-rich plasma by biodegradable gelatin hydrogel.Tissue Eng 2005,11:1224- 1233
26.Meisel R,Zibert A,Laryea M,et al.Human bone marrow stromal cells inhibit all-ogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan de-gradation.Blood.2004;103:4619-4621.
1. Sullivan JA ,Oettinger HF,Sachs DH ,et all Analysis of polymorphismin porcine MHC class I genes,alteration in signal's recognized by human cytotoxic lymphocytes[J ].J Immunol, 1997 ,159 ;2318-2325
2. Silva WAJ, Covas DT, Panepucci RA, et al. The profile of gene expression of human marrow mesenchymal stein Cells[J]. Stein Cells, 2003, 21(6): 661-669.
3. Lazarus HM, Haynesworth ES, Gerson SL, et all Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal rogenitor cells); implication for therapeutic use. Bone Marrow Transplant, 1995,16 ( 4) : 557-564.
4. Maitra, B; Szekely E; Gjini K; et al. Human mesenchymal stem cells support unre-lated donor hematopoietic stem cells and suppress T-cell activation. Bone marrow Transplantation, Mar2004, Vol. 33 (6), 597-604
5. Niemeyer P, Seckinger A, Simank HG, et al. Allogenic transplantation of human mesenchymal stem cells for tissue engineering purposes: an in vitro study [J].Orthopade 2004,33(12): 1346-1353
6. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance.cell,2001; 101:455-458.
7. Plumas, J Chaperot, L Richard, MJ, et al. Mesenchymal stem cells induce apoptosis of activated T cells.Leukemia,2005,19(9): 1597-1604
8. Pascher A , Poehlein C ,Stangl M,et all Application of immunoapheresis for delayi-ng hyperacute rejection during isolated xenogeneic pig liver perfusion[J ].transpla-ntation , 1997,63 :86-71
9. Candinas D ,Bach FH , Hancok WW1 Delayed xenograft rejection in complement-depleted T-cell-deficient rat recipients of guinea pig cardiac grafts[J ].Transplant Proc , 1996 ,28 :67-81
10. Ruggeri L,Capanni M,Martelli MF,et al.Cellular therapy:exploting NK cell allureactivity in transplantation[J].Curr Opin Hematol 2001,8(6):355-359.
11.Ristich V,Liang S,Zhang W,et al.Tolerization of dendritic cells by HLA -G[J].EurJ Immunol,2005,35(4): 1133-1142.
12. Gotherstrom C,Ringden O,Tammik C,et al.Immunologic propertie of human fetal mesenchymal stem cells[J].Am J Obstet Gynecol 2004,190(1):239-245.
13.X u XL, Tang T, Dai, et al. K Immune response and effect of adenovirus mediated human BMP-2 gene transfer on the repair of segmental tibial bone defects in goats. Acta Orthop 2005; 76(5):637-646.
14. ZhangW, GeW, Li C, et al. Effects ofmesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem CellsDev, 2004; 13:263-271.
15. Sun S, Guo Z, Xiao X. Isolation ofmouse marrow mesenchymal p rogenitors by a novel and reliable method [ J ]. Stem Cells, 2003, 21 (5) : 527 - 535.
16. Dong H,Zhu G,Tamada K,et al.B7-H1,a third member of the B7 family,costimulates T-cell proliferation and secretion of interleukin 10 [J].Nat Med,1999,5:1365-1369.
17. Dong H,Strome SE,Matteson EL,et al.costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis [J]. J Clin Invest, 2003,111:363-370.
18. Dong H,Strome SE,Salomao DR,et al.Tumor associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion [J]. Nat Med, 2002,8:793-800.
19. Mazanet MM,Hughes CC. B7-H1 is expressed by human endothelial cell and suppresses T cell cytokine synthesis [J]. J Immunol,2002,169:3581-3588.
20. Schreiner B,Mitsdoerffer M,Kieseier BC,et al. Interferon beta enhances monocyte and dendritic cell expression of B7-H1(PD-L1), a strong inhibitor of autologous T-cell activation:relevance for the immunemodulatory effect in multiple sclerosis [J]. J Neuroimmunol,2004,155(122): 172-182.
21.Tamura H,Dong H,Zhu G,et al.B7-Hl costimulation preferentially enhances CD28" independent T-helper cell function [J]. Blood, 2001,97:1809-1816.
22. Gray CP,Arosio P,Hersey P. Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells [J]. Blood,2002,99:33263-3334.
23. Blank C, Brown I, Peterson AC,et al. PD-LI/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8~+ T cells. Cancer Res, 2004, 64: 1140-1145.
24. SICA GL, CHOI IH, ZHU G, et al. B7-H4 , a molecule of the B7 family, negatively regulates T cell immunity [ J] . Immunity, 2003, 18( 6) : 849- 861.
25. SEDY JR, GAVRIELI M, POTTER KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator [ J] . Nat Immunol, 2005, 6(1): 90- 98.
26. GONZALEZ LC, LOYET KM, CALEMINE-FENAUX J, et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator [ J] . Proc Natl Acad Sci USA, 2005, 102 ( 4): 1116-1121.
27. CHEN L. Co-inhibitory molecules of the B7-CD28 family in the control of T cell immunity[ J] . Nature Rev Immunol, 2004, 4: 336- 347.
1.Bartholomew A,Sturgeon C,Siatskas Metal.Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo[J].Exp Hematol 2002;30(1):42-48.
2.Sudeepta Aggarwal and Mark E Pittenger Human mesenchymal stem cells modulate allogeneic immune cell responses blood.2005;105(4):1815-1822.
3.LeBlanc K,Rasmusson I,Gotherstrom C,et al.Mesenchymal stem cells inhibit the expression of CD25(interleukin-2 receptor) and CD38 on phytohaemag glutinin activeated lymphocytes.Scand J Im munol.2004;60(3):307-15
4.Plumas,J Chaperot,L Richard,MJ,et al.Mesenchymal stem cells induce apoptosis of activated T cells.Leukemia,2005,19(9): 1597-1604
5. Butler PE; Lee WP; Sims M et al. Cell transplantation from limb allografts. Plast Reconstr Surg, 1998; 102(1): 161-8.
6. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-3843.
7. Bartholomew A, Sturgeon C, Siatskas M,et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental Hematology 30 (2002) 42-48.
8. Plumas J, Chaperot L, Richard MJ, et al. Mesenchymal stem cells induce apoptosis of activated T cells.Leukemia,2005,19(9): 1597-1604
9. Maitra B, Szekely E, Gjini K,et al.Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 2004 Jan 12.
10. Djouad F, Plence P, Bony C,et al.Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003 Nov 15; 102(10): 3837-3844.
11. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31:890-896
12. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol.2003; 57:11-20.
13. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-3843.
14. Krampera M,Glennie S,Dyson J,et al.Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen specific T cell to their cognate peptide[J].Blood,2003,101(9):3722-3729.
15.Tse WT, Pendleton JD, Beyer WM,et al.Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003 Feb 15; 75(3): 389-397.
16. Zhang Y,Li CD,Jiang XX,et al.Comparison of mesenchymal stem cells from human placenta and bone marrow [J].Chin MedJ(Eng),2004,117(6):882-887.
17. Silva WAJ,Covas DT,Panepucci RA,et al.The profile of gene expression of human marrow mesenchymal stem cells[J].Stem Cells,2003,21(6):661-669
18. Taniguchi F,Harada T,Deura I,et al.Hepatocyte growth factor promotes cell proliferation and inhibits progesterone secretion via PKA and MAPK pathways in a human granulosaxell line[J].Mol reprod dev,2004,68(3):335-344.
19. Arikawa T,Omura K,Morita I. Regulation of bone morphogenetic protein expression byendo genous prosta glandinE2 in human mesenchymal stem cells[J].JCellPhysiol, 2004,200(3):400-406.
20. Roper RL,Ludlow JW,Phipps RP.Prosta glandinE2 inhibits Blym phocyte activati-on by a cAMP dependent mechanism:PGE induc iblere gulatory proteins[J]. Cell immunol, 1994,154(1):296-308
21.Akasaki Y,Liu G,Chung NH,etal.Induction of a CD4+Tregutory typel response by cyclooxygenase 2 overexpressingglioma[J]JImmunol,2004,173(7):4352-4359.
22. Colgan SP.Lipid media torsin epithelial cell cell interactions[J]. Cell Mol Life Sci,2002,59(5):754-760.
23. Meisel R,Zibert A,Laryea M,etal.Human bone marrow stromal cells inhibit allogeneic T cell responses by in doleamine2,3dioxygenase mediated tryptophan degradation[J]. Blood,2004,103(12):4619-4621.
24. Frumento G,Rotondo R,Tonetti M, etal.Tryptophan derived catabolite sare responsible for inhibition of Tand natural killer cell proliferation induced by indoleamine2,3 dioxygenase[J].JExpMed,2002,196(4):459-468.
25. Yard BA, Kooymans Couthino M, Pape M E. Analysis of cytokine production by graft-infiltrating cells isolated from rejecting renal allografts. Transplantation, 1994, 57(1):153
26. Salom RN, Maguire JA, Hancock WW Mechanism of a clinicallyrelevant protocol to induce tolerance of cardiac allografts.Transplantation, 1993; 56:1309-14.
27. Ditmer R, Harfmann P, Tenschert Wet al. Monitoring of renal transplant patients with interleukin-2 and interleukin-2 receptor enzyme immunoassay and interleukin-2 receptor immunocytology.TransplantProc,1990;22:2284-5.
28.Docke WD,Randow F,Syrbe U.Monocyte deactivation in septic patients:Restoration by IFN-γ treatment.Nature Med 1997,3(6):678.
29.Sherman LA,Chatopadhyay S.The molecular basis of alloreconition Ann Rev Immunol,1993;11:385-402.
30.Devine SM,Peter S,Martin B J,et al.Mesenchymal stem cells:stealth and suppression.Cancer J,2001;7(SuppI 2):S76-82.
31.Mclntosh K,Bartholomew A.Stromal cell modulation of the immune system.A potential role for mesenchymal stem cells.Graft,2000;3:324-8
32.Maitra B,Szekely E,Gjini K,et al.Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation.Bone Marrow Transplantation,Mar2004,Vol.33(6):597
33.阳富春,杨志明,李秀群,等.组织工程化骨修复称猴长段骨缺损的实验 中国修复重建外科杂志,2003:17:406-10
34.Aggarwal S,Pittenger MF.Human mesenchymal stem cells modulate allogeneic immune cell responses.Blood.2005 Feb 15;105(4):1815-22.Epub 2004 Oct 19.
35.Eiselt P,Kim BS,Chacke B.Development of technologies aiding large-tissue engineering.Biotechnol Prog,1998;14:134-40
36.Le Blanc K,Tammik L,Sundberg B,et al:Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.Scand J Immunol.2003;57:11-20
37.Fibbe WE.Modulation of Immune responses by Mesenchymal Stem Cells.Ann N Y Acad Sci.2007 Apr 18
38.Poncelet AJ,Vercruysse J,Saliez A,et al Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro,intracardiac injection elicits an immune response in vivo.Transplantation.2007 Mar27;83(6):783-90
1. Vacanti CA,Vacanti JP.Bone and cartilage reconstruction with tissue engineering approaches.Otolaryngol Clin North Am,1994,27(1):263.
2. Crane GM,Ishaug SL,Mikos AG,et al.Bone tissue engineering.Nat-Med, 1995, 1(12): 1322.
3. Wakitani S, Saito T, Caplan A. Myogenic cells derived fromrat bone marrow mesenchymal stem cells expoed to 5-azacytidine.MuscleNerve,1995,18(12): 1417-1426.
4. Phinney DG, Kopen G, Isaacson RL, et al. Plastic adherent stromal cells from the bone marrow of commonly used strain so inbredmice: variationin yield, growth, and differentiation. J Cel Biochem,1999,72(4):570-585.
5. Hua L, David M K, Boon CH1, et al. The Immunogenicity and Immunomodulatory Function of Osteogenic Cells Differentiated from Mesenchymal Stem Cells. The Journal of Immunology, 2006, 176: 2864-2871.
6. Friedenstein, A. Stromal monocytes of bone marrow: cloning in vitro and retransplantation in vivo. In: S. Thiernfelder, Editor, Immunology of Bone Marrow Transplantation, 1980, 19.
7. Friedenstein A J,Gorskaja U, Kalugina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs.Exp Hemato,1976,1(4):267-302
8. Guo ZK, Yang JQ, Liu XD, et al. Biological features of mesenchymal stem cells from human bone marrow. Chinese Medical Journal, 2001, 114(9): 950-95.
9. Lagar'kova MA, Lyakisheva AV,Filonenko ES,et al. Characteristics of human bone marrow mesenchymal stem cells isolated by immunomagnetic selection. Bull Exp Biol Med. 2006;141(1):112-6.
10. Simmons PJ, Torok-Storb B (1991) Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 78(1):55-62 .
11. Deschaseaux F, Gindraux F, Saadi R, et al. (Direct selection of human bone marrow mesenchymal stem cells using an anti-CD49a antibody reveals their CD45~(med.low) phenotype. Br J Haematol. 2003, 122(1-2):506-517.
12. Reyes M.,. Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone marrow, J. Clin. Invest, 2002, 109 (2), 337-346.
13. Gindraux F, Selmani Z, Obert L, et al.Human and rodent bone marrow mesenchymal stem cells that express primitive stem cell markers can be directly enriched by using the CD49a molecule. Cell and Tissue Research, 2007, 327(3): 471-483.
14. Letchford J, Angharad MC, Karina S, et al. Isolation of C15: A novel antibody generated by phage display against mesenchymal stem cell-enriched fractions of adult human marrow. Journal of Immunological Methods, 2006, 308( 1-2): 124-137.
15. Stewart K, Monk P, Walsh S, et al. STRO-1, HOP-26 (CD63), CD49a and SB-10 (CD166) as markers of primitive human marrow stromal cells and their more differentiated progeny: a comparative investigation in vitro. Cell Tissue Res, 2003, 313(2):281-290
16. Guo KT, SchAfer R, Angela P, et al. A New Technique for the Isolation and Surface Immobilization of Mesenchymal Stem Cells from Whole Bone Marrow Using High-Specific DNAAptamers. Stem Cells Vol. 2006, 24(10 ): 2220-2231.
17. Tondreau T, Lagneaux L, Dejeneffe M, et al. Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential. Cytotherapy. 2004;6(4):372-379.
18. Le Blanc K, Tammik C, Zetterberg E, et al. HLA-expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol, 2003,31(10): 890-896.
19. Niemeyer P, Krause U, Punzel M, et al. Mesenchymale Stammzellen zum Tissue zngineering von Knochen: 3-D-Kultivierung und Osteogene Differenzierung auf mineralisier-tem Kollagen. Z Orthop, 2003,141 (3): 712-717.
20. Maitra B, Szekely E, Gjini K, et al. Human mesenchymal stem ceils support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant, 2004, 33(6): 597-604.
21. Rasmusson I, Ringden O, Sundberg B, et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but notactivated cytotoxic T lymphocytes or natural killer cells. Transplantation, 2003, 76(8): 1208 1213
22. Klyushnenkova E ,Mosca J ,Mclntosh K. Human mesenchymal stem cells suppress allergenic t ransplantation. Blood , 1998 ,92 :642-651.
23. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stein cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide[J]. Blod, 2003, 101(9):3722-3729.
24. Tse WT, Pendleton JD, Beyer WM. et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation[J]. Transplantation, 2003, 75(3): 389-397.
25. Le Blanc K, Rasmusson I, Gotherstrom C, et al. Mesenchymal stein cells inhibit the expression of CD25(interleukin-2 receptor)and CD38 on phytohaemagglutinin-activated lymphocytes [J]. Scand J Immunol, 2004, 60(3): 307-315.
26. Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stein cells induce division arest anergy of activated T cells[J]. Blod, 2005, 105(7): 2821-2827.
27. Wei Zhang, Wei Ge, Changhong Li, et al. Efects of mesenchymal stem cells Oil difierentiation. Maturation and funotion of human monocyte-derived dendritic Cells[J]. Stem Cells and Development, 2004, 13: 263 -271.
28. Silva WAJ, Covas DT, Panepucci RA, et al. The profile of gene expression of human marrow mesenehymal stein Cells[J]. Stein Cells, 2003, 21(6): 661-669.
29. Taniguchi F, Harada T, Deura I, et al. Hepatocyte growth factor promotes cell proliferation and inhibits progesterone secretion via PKAand MAPK pathways in a human granulosa cell line. Mol Reprod Dev, 2004, 68(3): 335-342.
30. Arikawa T, Olnura K, Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stein ceils[J]. J Cell Physiol, 2004, 200(3): 400-406.
31.Meisel R, Zibert A, Laryea M, et al. Human bone marrow strolnal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation[J]. Blod, 2004, 103(12): 4619-4621.
32. Le Blanc K, Tammik 1 , Sundberg B, el al. Mesenchymal stem cellsinhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompalm y complex[J]. Scand J Immunol, 2003, 57: 11-20.
33. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growt h in allogeneic animals. Blood ,2003 ,102(38):372-384.
34. De Kok IJ, Peter SJ, Arehambauh M, et al. Investigation of allogeneic mesenc·hyrnal stem cell—based alveolar Irene formation: preliminary findings[J]. Clin Oral Implants Res. 2003, 14: 481-489.
35. Arinzeh I'L, Peler SJ, Archambauh MP, et al. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect[J]. J Bone Joint Surg Am, 2003, 85-A: 1927-1935.
36. Hiroyuki T,Junichi H, Eric C, Engineered allogeneic mesenchymal stem cells repair femoral segmental defect in rats. Journal of Orthopaedic Research 21 (2003) 44-53
1. Kosmaczewska A, Magott-Procelewska M, Frydecka J, et al CD40L, CD28, and CTLA-4 expression on CD4~+ T cells in kidney graft Recipients a relationship with post-transplantation clinical course [J]. Transpl Immunol, 2006,16(1):32- 40.
2. Van-Berkel M E, Oostenvegel M A. CD28 and ICOS similar or separate costimulators of T cells [J]. Immunol Lett, 2006, 105(2): 115-122.
3. Borst J, Hendriks J, Xiao Y, CD27 and CD70 in T cell and B cell activation [J].Curr Opin Immunol, 2005,17( 3): 275-281.
4. Dong H,Zhu G,Tamada K,et al.B7-Hl,a third member of the B7 family,costimulates T-cell proliferation and secretion of interleukin 10 [J].Nat Med, 1999,5:1365-1369.
5. Dong H,Strome SE,Matteson EL,et al.costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis [J]. J Clin Invest, 2003,111:363-370.
6. Dong H,Strome SE,Salomao DR,et al.Tumor associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion [J]. Nat Med, 2002,8:793-800.
7. Mazanet MM,Hughes CC. B7-H1 is expressed by human endothelial cell and suppresses T cell cytokine synthesis [J]. J Immunol,2002,169:3581-3588.
8. Schreiner B,Mitsdoerffer M,Kieseier BC,et al. Interferon beta enhances monocyte and dendritic cell expression of B7-H1(PD-L1), a strong inhibitor of autologous T-cell activation:relevance for the immunemodulatory effect in multiple sclerosis [J]. J Neuroimmunol,2004,155(122):l72-182.
9. Tamura H,Dong H,Zhu G,et al.B7-Hl costimulation preferentially enhances CD28~-independent T-helper cell function [J]. Blood, 2001,97:1809-1816.
10. Gray CP,Arosio P,Hersey P. Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells [J]. Blood,2002,99:33263-3334.
11. Freeman GJ,Long AJ,Malenkovich N,et al.Enganement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J]. J Exp Med,2000,192:1027-1034.
12. Ishida Y,Agata Y,Shibahara K,et al. Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily ,upon programmed cell death [J]. EMBO J, 1992,11:3887-3895.
13. Finger LR,Pu J,Wasserman R,et al. The human PD-1 gene:complete cDNA , genomic organization , and developmentally regulated expression in B cell progenitors [J]. Gene, 1997,197:177-187.
14. Prokunina L,Castilejor opez ,Oberg ,et 1.A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans [J] .Nat Genet ,2002,32:666-669.
15. Strome SE,Dong H,Tamura H,et al.B7-Hl blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma[J]. Cancer Res, 2003,63(19):6501-6505.
16. Tyler J.Curiel,Shuang Wei,Haidong Dong,et al.Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity[J]. Nat Med, 2003,9(5):562-567.
17. Sica GL , Choi IH , Zhu G, et al . B72H4 , a molecule of the B7 family, negatively regulates T cell immunity [J] . Immunity , 2003 ,18(6): 849 - 861.
18. Zang X, Loke P , KimJ , et al. B7x : a widely expressed B7 family member that inhibits T cell activation [J ] . Proc Natl Acad Sci ,2003 ,100(18) :10 388 - 10 392.
19. Prasad DV , Richards S , Mai XM, et al . B7S1 , a novel B7 family member that negatively regulates T cell activation[J] .Immunity ,2003 ,18(6) :863 - 873.
20. Choi IH , Zhu G, Sica GL , et al . Genomic organization and expression analysis of B72H4 , an immune inhibitory molecule of the B7 family [J ] . J Immunol ,2003 ,171 (9): 4 650 -4 654.
21. Hirotsune S , Yoshida N , Chen A , et al . An expressed pseudogene regulates the messenger-RNA stability of its homologous coding gene [J] . Nature , 2003 ,423(6 935) :91 -96.
22. Anderson HA , Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation [J ] . Nat Immunol, 2000 ,1(2) : 156 - 162.
23. Tringler B , Liu W, Corral L , et al . B72H4 overexpression in ovarian tumors[J ] . Gynecol Oncol, 2006 ,100(1) :44 - 52.
24. Tringler B , Zhuo S , Pilkington G, et al . B72h4 is highly expressed in ductal and lobular breast cancer [J ] . Clin Cancer Res ,2005 ,11(5) :1 842 - 1 848.
25．李文桦,刘瑞梓,杨秀利,等．肿瘤模型中B7-H4和BTLA的异常表达[J]．中国癌症杂志,2005,15(04)：313—316．
26. Simon I, Zhuo S , Corral L , et al . B72h4 is a novel membrane2bound protein and a candidate serum and tissue biomarker for ovarian cancer [ J ] . Cancer Res , 2006 , 66 (3):1 570- 1 575.
27. Kryczek I, Zou L , Rodriguez P , et al. B72H4 expression identifies a novel supper-ssive macrophage population in human ovarian carcinoma [ J ] . J Exp Med , 2006 , 203 (4) :871 -881.
28. Salceda S , Tang T, Kmet M, et al . The immunomodulatory protein B72H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation [J ] . Exp Cell Res , 2005 ,306(1) : 128 - 141.
29. Tamada K, Shimozaki K, Chapoval AI, et al . Modulation of T-cell2mediated immunity in tumor and graft-versus2host disease models through the LIGHT co2stimulatory pathway[J] . Nat Med , 2000 ,6(3) :283 - 289.
30. Tamada K, Tamura H , Flies D , et al . Blockade of LIGHT/LT beta and CD40 signaling induces allospecific T cell anergy , preventing graft2versus2host disease [J ] . J Clin Invest, 2002 ,109(4) :549 - 557.